New York State Common Retirement Fund lifted its stake in shares of AnaptysBio Inc (NASDAQ:ANAB) by 56.2% during the first quarter, HoldingsChannel reports. The firm owned 21,839 shares of the biotechnology company’s stock after acquiring an additional 7,855 shares during the period. New York State Common Retirement Fund’s holdings in AnaptysBio were worth $2,273,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of AnaptysBio during the 1st quarter worth about $173,000. Two Sigma Securities LLC bought a new position in shares of AnaptysBio during the 4th quarter worth about $212,000. Smith Asset Management Group LP bought a new position in shares of AnaptysBio during the 1st quarter worth about $243,000. Amalgamated Bank bought a new position in shares of AnaptysBio during the 4th quarter worth about $244,000. Finally, Raymond James Financial Services Advisors Inc. bought a new position in shares of AnaptysBio during the 4th quarter worth about $252,000.
Shares of NASDAQ ANAB opened at $74.91 on Monday. AnaptysBio Inc has a fifty-two week low of $20.12 and a fifty-two week high of $134.00. The company has a current ratio of 17.57, a quick ratio of 17.57 and a debt-to-equity ratio of 0.02.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.19). During the same quarter last year, the company earned ($0.75) EPS. equities research analysts anticipate that AnaptysBio Inc will post -3.04 earnings per share for the current fiscal year.
ANAB has been the topic of a number of research analyst reports. Stifel Nicolaus set a $152.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a research report on Monday, March 26th. Zacks Investment Research cut shares of AnaptysBio from a “hold” rating to a “sell” rating in a research report on Friday, May 11th. Royal Bank of Canada increased their price objective on shares of AnaptysBio to $144.00 and gave the stock an “outperform” rating in a research report on Friday, March 2nd. ValuEngine raised shares of AnaptysBio from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. Finally, JMP Securities set a $180.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a research report on Tuesday, March 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $131.44.
In related news, Director Nicholas Lydon sold 33,000 shares of the firm’s stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $86.88, for a total value of $2,867,040.00. Following the transaction, the director now owns 301,506 shares of the company’s stock, valued at approximately $26,194,841.28. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 20.80% of the stock is currently owned by company insiders.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.